HS

Henry Schein, Inc.

HSICHealthcareNASDAQ

Medical Distribution

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$13.18B
+4.0% YoY
Net Income
$398.0M
+2.1% YoY
EBITDA
$964.0M
+5.7% YoY
Free Cash Flow
$446.0M

Scan Results

Daily timeframe
DateIndicatorDetails
Oct 16▲ MACD Positive CrossoverHistogram +0.2804, positive momentum
Oct 15▲ MACD Positive CrossoverHistogram +0.1306, positive momentum
About Henry Schein, Inc.

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. The $9.68B market capitalization puts HSIC squarely in mid-cap range for its industry. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments.

Where HSIC stands vs its 150-day and 200-day moving averages

As of the October 16, 2026 close, HSIC finished 6.79% above its 150-day moving average ($81.46) and 7.90% above its 200-day moving average ($80.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is HSIC overbought or oversold?

At the October 16, 2026 close, HSIC's RSI(14) was 53.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$9.68B
P/E (TTM)25.06
Fwd P/E14.17
EPS$3.39
Beta0.84
52W Change+33.1%
Dividend Yield0.00%
ROE8.8%
Analysis

On the balance sheet, HSIC has $157.0M in cash with $3.81B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $446.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 8.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.4% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $12.65B (2022) to $13.18B (2025).

The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HSIC.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms